HUTCHMED (China) Ltd
HCM
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,735.40 | 83.10 | -0.94% |
| CAC 40 | 7,987.49 | 0.00 | 0.00% |
| DAX 40 | 24,307.92 | 357.35 | 1.49% |
| Dow JONES (US) | 49,686.12 | 159.95 | 0.32% |
| FTSE 100 | 10,323.75 | 128.38 | 1.26% |
| HKSE | 25,675.18 | 287.55 | -1.11% |
| NASDAQ | 26,090.73 | 134.41 | -0.51% |
| Nikkei 225 | 60,815.95 | 593.34 | -0.97% |
| NZX 50 Index | 12,845.41 | 82.49 | 0.65% |
| S&P 500 | 7,403.05 | 5.45 | -0.07% |
| S&P/ASX 200 | 8,505.30 | 72.60 | -0.85% |
| SSE Composite Index | 4,131.53 | 3.86 | -0.09% |